

Portfolio of Israeli companies Life science and Clean-tech sectors October 2020

Edited by the Manufacturers Association of Israel

For additional information, please contact Yael Shechter-Sitman E-mail: <u>yael.s@industry.org.il</u>

Table of contents

Cleantech:

Waste solutions

1. Aqwise – Wise Water Technologies Ltd.

- 2. Clariter
- 3. GES
- 4. Negev Ecology
- 5. Pillar
- 6. VPM Plast

<u>Energy</u>

- 7. Bazan Group
- 8. Brenmiller Energy
- 9. NAM Technology
- 5. Pillar

Biochemistry

- 10. Delek industries
- 11. Dor Chemicals

Pharmaceutical

- 12. Concept for Pharmacy
- 13. Dexcel Pharma
- 14. Mapi Pharma
- 15. Unipharm

Medical cannabis

16. Cannbit-Tikun-Olam

Medical Devices

- 17. Common Sense
- Medispec
- 18. 19. Savyon Diagnostics
- 20. Simbionix (simulators)

Laboratories

- 21. Patho-Logica
- 22. **Smart Assays**

<u>Veterinaria</u>

23. Biovac



• Tel: +972-9-959-1901 • Fax: +972-9-959-1903 • 8 Hamenofim St., P.O. Box 12615, Herzliya 46733 ISRAEL • www.aqwise.com

Aqwise – Wise Water Technologies Ltd. **Company Profile**

Aqwise is an Israeli-based company, with global presence, providing advanced solutions for wastewater and water treatment applications - for both municipal and industrial applications. For new treatment plants, and upgrade, expansion and retrofit of existing ones.

With over 20 years of experience, and more than 600 installations world-wide in over 55 countries, we are true leader in our field.

Aqwise solutions are based in most on biofilm-based processes, utilizing our proprietary Aqwise Biomass Carriers. These include both aerobic (MBBR, IFAS) and anaerobic (DANA, DACS) processes - for treatment of municipal and industrial wastewater, and also surface and ground water.

Our services portfolio ranges from supply of "Process Package" to engineering companies to full project engineering and Turnkey construction of treatment plants.

With our Head Office in Israel, Aqwise currently has offices also in Europe (UK, Italy, Germany, Spain), Latin America (Mexico) and India.

Subsidiary companies include Agana BV and Agwise Europe BV, both registered in the Netherlands.

Aqwise would be interested to connect with leading engineering and EPC companies who are involved in wastewater treatment projects, for both the public and private sectors.

Please feel free to contact Mr. Marc Krieger – VP Sales: marc@aqwise.com; +972 544 305 718

For further information please visit our website: www.aqwise.com



Proprietary and Confidential. © Copyright 2020 Aqwise - Wise Water Technologies Ltd.

WE TAKE PLASTIC NOBODY WANTS AND TRANSFORM IT INTO PRODUCTS EVERYBODY NEEDS

Clariter is a global cleantech innovator that has created a revolutionary process, which impacts the world's plastic waste problem as well as the dependency on petrochemicals derived from crude.

PROBLEM

Today plastic waste is a global epidemic, according to the UN. The world is striving to find a solution which ends the life of plastic waste and doesn't harm our environment. Prices of crude oil and fossil fuels are volatile and rising. Tougher regulations are being imposed on industries. And finally, brand owners face growing consumer demands for cleaner and sustainable solutions. Clariter has a solution to address these problems.

TECHNOLOGY

Our unique, patented process transforms plastic waste into high - value, pure products for multiple industries. While others recycle plastics to other plastics and fuel, we upcycle waste into value.

END PRODUCTS

We make odorless solvents, snowwhite waxes and pure oils. Clean, sustainable, cost-effective, meeting the highest standards.


DCO

1000+ APPLICATIONS

Our end products are used as ingredients in many applications for every-day use that are usually made from crude oil: from candles and furniture polish, to car wax, detergent and cleaning material.

IMPACT

- Each Clariter plant cleans the environment from 60,000 tons of plastic waste annually.
- Turns waste into value while being CO² negative.
- Reduces the dependence on crude oil with volatile prices.
- Creates new business opportunities and jobs for local communities.
- Helps to meet the UN Sustainability Development Goals (SDGs) and allows companies to meet their Corporate Social Responsibility (CSR) criteria.



LET'S KEEP TALKING!

Please find more information on our website, while we will be glad to answer any other questions you might have.

www.clariter.com | info@clariter.com

GES Your environmental expert

GES CORPORATE OVERVIEW

Founded in 1988, GES is 100% owned by Generation Capital, a listed Energy & Infrastructure Investment fund, with assets worth of more than 250M NIS, that provides exposure to investments in infrastructure and energy, with an emphasis on improvements and value creation.

Projects Division

Our experienced staff and proven track record of successful projects offer customers best available technology and most reliable and cost-effective solutions. GES offers overall water treatment services featuring technical, conceptual, planning and interpersonal abilities.

Operation and Maintenance Division

Our operation and maintenance division ensure that the system performs as designed while maximizing its production, economic and environmental benefits. GES provides a complete package of O&M services for new, retrofitted and existing plants.


Industrial Chemicals Division

GES develops, manufactures, imports and distributes high quality, green chemistry based products meeting the most strict standards. GES chemicals division offers a top quality products for the variety of the applications such as: gluing, lubrication, surface coating, on-site treatment and water treatment chemicals.

BUSINESS AREAS



Desalination





Industrial & Municipal Waste Water Treatment



Chemicals for

Industrial Applications

Operation and Maintenance (O&M)

MULTI-DISCIPLINARY IN-HOUSE EXPERTISE

For 30 years GES has been delivering comprehensive environmental solutions and services to a variety of governmental, municipal and industrial sectors.

Amongst our customers are governmental authorities, military entities, leading EPC companies, power stations, petrochemical, food & beverage and other facilities.

Our multi-disciplinary and highly knowledgeable in-house team excels at integrating best available technology (BAT) into cost-effective, reliable and environment-friendly solutions that meet each client's unique requirements.







About Negev Ecology

Negev ecology is An Israeli company which specializes in recycling and treatment of waste materials and products of different types, providing comprehensive recycling solution from early stage of collecting and transporting salvage materials to their transformation into raw materials of a high standard and quality for recycle and reuse in the industry and extensive experience in exporting products.

Negev Ecology is seeking for partners and buyers (factories, mills, companies) for their waste products: Paper, cardboard, plastic scraps, organic waste as well as knowledge transferring. The company interested in expanding its customer base and penetrating new markets all over the world. They are seeking a distribution services agreement or a services agreement with a company to sell and/or convert the paper and plastic recyclable materials, which the Israeli company will be offering.

Our expertise:

Company's expertise ranges: Recycling and treatment of waste materials and products of different types.

The company owns a large number of facilities, landfills sites, recycling plants and fleet of 100 trucks

Company Activities:

- Recycling, collection and transportation of various waste.
- Separation systems management
- Wastewater and organic mineral treatment.
- Evacuation and treatment of contaminated lands.
- Development of Green energy installations.
- Destruction of special waste.
- Management and operation of landfill sites.
- Evacuation and treatment of poultry carcasses.
- Construction waste recycling
- Yard waste collection and crushing
- Asbestos removal
- Sludge treatment

OUR IP IS YOURS

Development of SMART POLYMERS and Waste Treatment Solutions for Industry

Since 2000 Pillar Ltd is devoted to industry. Pillar Ltd is an Outsource R&D Project Management Company, specializing in customized application development for Industrial clients. The company offers a unique service model; All technology and IP are owned by the client. This model allows industries to upgrade and develop technological applications utilizing international and Israeli grant programs and incentives.

The company's main laboratory work is performed in the Hebrew University of Jerusalem while it is operating within various global industrial facilities. The company's expertise is focused on polymeric molecular design: tailoring polymer properties using chemical compositions for characterization deviations for physical, chemical and enzymatic targeted performances. Application range from Cosmetics, medical, active release systems, recycling, reinforced materials, fabrics and others.

Thank her clients and partners for developing a better world together

esc

Tama

Dexcel

pharma

Oridion.

PILLAR LTD Smart Materials Smart Products

Prof. Yoel Sasson: Organic Chemistry. Prof. Gad Maron: Reinforced Polymers. Prof. Alex Sivan: Polymer Biochemistry. Dr. Shai Garty: Smart Polymer Engineer. Yair Yarkoni: Glue and adhesives apps. Asher Razlan: Commercial Chemistry. Omar Elzinaty: Pharmaceutical Polymers.

Management & Business Development: Ariel Brosh, Tal Cohen, Harel Israeli.

> TEXAS INSTRUMENTS AVAYA

Out-Source Technology R&D Team and Advisory

Prof. Daniel Cohn: Medical & Reactive Polymers. Prof. Ovadia Lev: Water Technologies. Dr. Uri Stoin: Organic Chemistry Engineer. Dr. Ariel Givant: Smart Polymer Engineer. Ysaac Oppenheim: Smart Textiles. Keren-Or Hasson: Medical Polymers Engineer. Malak Daood: Reactive Polymers Engineer.

Funding and Strategy: Sharon Schreiber. R&D Coordination: Alex Braun.

Contact: pillarltd@outlook.com Tel: +97246043336 Fax: +97246043337

RAD



VPM Plast LTD – Company profile

VPM Plast Ltd is a leading Israeli company in recycling industrial plastic waste.

The company was established in 2006 as a private company located in Kibbutz Yasur in the northern Israel.

VPM Plast production, includes a full recycling solution, starting with collection of industrial plastic waste from factories in Israel and overseas, grinding, washing and extrusion of a large number of recycled plastic waste materials.

Our company has ISO 9001 certification.

The company emphasizes innovation in the production process and machinery.

The **Raw Materials** produced by our company help reduce the waste plastic burial and replace virgin raw materials in other plastic production factories therefore helping maintain a better and cleaner environment.

VPM Plast is interested in collaboration with companies that operate in the recycling industries in the following fields of operation:

- Purchase of industrial plastic waste such as: PP/PE/PS/PC from: bales, powder, regrind etc.
- Sale of recycled raw material such as: PP/PE/PS/PC according to customer technical request with full TDS.
- Innovation in recycling operation and machinery.

Looking forward to cooperating with you!

Zohar Vodrrero

CEO

VPM Plast Ltd.

zoharv@vpm-plast.com

www.vpm-plast.com



The energy and polymers engine of the Israeli Economy

Bazan Group is the largest energy and petrochemicals group of Israel and is the driving engine of the Israeli economy, supplying all varieties of fuels as well as essential other raw materials for many manufacturers in the state. The group's facilities, located in the Haifa Bay area, comprises one of the largest and sophisticated refinery and petrochemicals complexes in the east Mediterranean basin, with Nelson complexity index (for the refinery itself only) of 9.1. Its modern facilities enable Bazan to produce a large variety of oil refinery products for industry, transportation, agriculture, infrastructures and household consumption.

Bazan has a maximum production capacity of 9.8 million tons of crude oil per year (197,000 barrels per day). About 70% of the Company's products are distributed in the domestic market, while the remainder is exported, primarily for the eastern Mediterranean.

Bazan Group comprises of three industrial companies operating in Israel, primarily in the production of petroleum products, polymers used as raw materials in the plastics industry and aromatics compounds for the chemicals and petrochemicals industries.

The Group's plants operate synergistically in one compound in the Haifa bay, allowing Bazan to optimize the output of the refinery facilities. The flexibility of its production units and the integrated management of the facilities, enable Bazan to maximize its profit margins and create cost efficiency across the production, as well as operate in flexibility utilizing the most from market changes and opportunities. The Company also supplies power services to industrial customers in the Haifa Bay area as well as infrastructure services (storage and logistics of fuel products). In addition to its domestic operation, the Group owns and operates polypropylene plant in Holland and marketing hubs (including storage) in various relevant markets in the world. For more details please visit our website – www.bazan.co.il

Bazan Group also focuses in innovation, mainly in the energy and plastic industries and won a governmental tender for the establishing and operating of innovation lab in the fields of environmental technologies and sustainability, encouraging and cultivating innovative ideas and growing technologies.

Bazan is a public company traded in the Tel-Aviv stock exchange, with the largest shareholder being the Israel corporation ltd.

For more information and enquiring about possible cooperation with Bazan Group, please contact the following -

Crude oil and fuels - Mrs. Limor Fasher Cohen, VP for integrated planning and trade: Plimor@bazan.co.il

Polyolefins, Aromatics and fuels domestic market -Mr. Mark Hanna, VP marketing and sales, purchases and contracting: Hmark@bazan.co.il

Innovation - Mrs. Einat Klein Kalach, Head of Innovation: Keinat@bazan.co.il

Other issues - Mr. Eli Mordoch, Company secretary: Emordoch@bazan.co.il



<u>About</u>

Brenmiller Energy provides sustainable thermal energy storage solutions. The company was founded by Avi Brenmiller, former CEO of Siemens CSP and Solel, and a team of experts in the field of renewable energy. Over the past 6 years we have developed an advanced thermal energy storage technology with a capital investment of \$70m. The company is traded on Tel-Aviv Stock Exchange with Market Cap of \$120m.

Technology

Our award-winning patented technology is based on storing heat at high temperatures of up to 750°c in crushed volcanic rocks. The storage is charged from different sources of energy – thermal, electric or both, and delivers energy on demand in the form of steam, hot water, air or electricity.



Key benefits

- Fuels savings up to 60% reduction in fuel costs
- Emission reduction enabling renewables and cleaner fuels
- Fast returns average project ROI of 4 years

Markets and business model

24% of global energy is used for industrial heat. While the electricity market is evolving rapidly to integrate renewable energy, the industrial sector is far from its emission reduction targets.

We're looking for collaboration with energy service companies, and in the industrial space where there is high thermal energy demand (food, chemicals, iron, plastic, paper).

Brenmiller will engineer, manufacture, and support warranty and remote monitoring. Local partners will do sales, installations and supply O&M.

Other applications: Heat recovery, Co-generation and combined cycle PP with storage, biomass projects.

Contacts:

Doron Brenmiller, EVP – doron@bren-energy.com Tal Tutnauer, Business Development – talt@bren-energy.com www.bren-energy.com New Authentic Mechanics



Israeli Registrar #515155281

CASCADE SOLUTIONS FOR SMART ENERGY SPENDING

Odem 33 B, P.O.B. 7363, Ma'alot, 2107149, Israel Tel/fax: +972-54-755-0034 \ofer@nam-technology.com www.nam-technology.com

NAM Technology Itd

Nam Technology (the Company) established in 2014 by team of scientists and entrepreneurs. The Company engaged in developing of technologies decreasing consumption of electricity and fuel spent for cooling logistic. The company technologies protected by local and international patents; the technology process certified by ISO-9001. The Company is member of Manufacturer Association of Israel.

Eco-kor is a device which saves energy spent for cooling process by commercial and industrial enterprises. Eco-kor can save 12%-15% of energy in medium temperature (4°) cooling storage, 20%-33% of energy for low temperatures (16°-20°) and more than 40% for very low temperature (about -30°) storage. With according to test performed logistic center of Tnuva (leader of Israeli food industry under inspection of Israeli Ministry of Environment, Eco-kor can save 20% of energy spent for cooling in environment of negative temperature (-18°). It means, saving rate of 27% in Abu Dhabi or Dubai, 22% in Florida, 17%-18% in Spain. Main Eco-kor customers are supermarket chains, food plants, cooling warehouses and hotels.

Eco-kor mobile is device for saving fuel (mainly, diesel) that used for cooling the refrigeration cargo trucks. Eco-kor mobile saves 15%-35% of fuel depends on the following conditions as transport refrigeration unit (TRU) size, climate terms and haul mode. Eco-kor mobile will be relevant also after replacement existing TRU by electrical units, because Eco-kor can save also electrical energy. The Eco-kor mobile customers are owner for cooling truck fleets.

Additionally, the company has technology enabling to increase efficiency of heat pumps and adsorption/absorption cooling machines.

The company team aware, UAE's HVAC market is giant, UAE's energy expenses spent for cooling and refrigeration are huge. We believe, implementation of the company technologies in UAE will allow significantly decrease the energy expenses there and will serve the environmental goal of the country.











Delek industries was purchase by Dayan Group, who was founded in 1987, as a multi- disciplinary group of companies, specializing in real estate, automotive and petrochemicals.

For the past six decades, Delkol brand has been setting the market standards for developing, manufacturing and delivering a complete line of tailor made

- Lubricants
- **Oils & additives**
- Metal working fluids •
- Unique and customized petroleum products •

Our products are meticulously customized to solve various customer needs within a number of different sectors.

In our in house R&D dept., our talented team of engineers works hand in hand with our customers, in order to provide customized products matching their exact needs.

With over 30 sales agents around the world, Delek has over 10,000 clients globally, in various sectors, starting from retail market such as gas stations, all the way through the industrial & institutional and automotive industries.

Our products comply with the highest quality standards of API and ACEA specifications. we are the first Israeli lubricants manufacturer to be awarded with ISO9001, ISO14001 and OHSAS18001.

Delkol holds OEM approvals of all main car manufacturers around the world



We also represent some of the world- class lubricants and automotive industries











Our main cooperation interests are:

- 1. Buying raw materials from UAE, such as base oils, additives, polymers, chemicals. Contact for suppliers: Adi Guttman, purchasing specialist adig@deleklubes.com
- 2. Selling our products, such as marine oils, lubricants, greases etc.

Contact for inquires: Itay Wineberger ,Regional sales manager itaiw@deleklubes.com



OR NOTHING AT ALL.

Delek Industries Ltd. | Yitzhak Rabin 1 St. Lod, Israel | Zip code 7130101 | POB 6040 Lod, Israel 7116001 | Headquarters: +972-8-9270801



DOR CHEMICALS

M100 technology - Using Methanol as Clean Alternative fuel

About Dor Chemicals

Founded in the early 1960s, Dor Chemicals is Israel's largest company for supplying methanol and its derivatives (such as: MTBE, HP-MTBE, Formaldehyde, resins, Hydrogen etc). Dor continually maintains high production quality and is certified for environment and safety standards according to ISO 9001:2008, ISO 14001:2004 & OHSAS 18001:2007. For more details visit our website at: <u>https://www.dor-group.com</u>

M100 engines

During the last decade, Dor has put an intensive R&D effort to expand the use methanol as a clean, safer, competitive alternative fuel and succeeded to developed & launch an Internal Combustion Engine running on 100% methanol (M100). The M100 engine leads to 85%-95% reduction in pollutant air emissions as well as reduction of up to 15% in CO₂ emissions, compare to diesel. Based on M100 engines, Dor is currently marketing M100 local-power Gensets that generating clean electricity. Using methanol instead of diesel reduces local air pollution form the gensets and enable to place them in sensitive areas close to the population (for example: construction sites, residential neighborhoods, etc.). At the same time, Dor is launching the first in the world medium heavy truck that runs on 100% methanol.





Business corporation with UAE:

Dor is looking for business partners & cooperation from the chemicals, energy or industrial sectors in the UAE, that supply or consume Methanol or with other partners who wish to collaborate in expanding the use of Methanol as a clean alternative fuel.

Contact info:

Mr. Lior Shmueli, Director – Methanol applicationsMobile:+972-50-7408987Email:liorsh@ecologicalfinance.com

Concept for Pharmacy Ltd



Introduction

Concept for Pharmacy is a privately owned pharmaceutical company that is manufacturing in three separate divisions. The first is a Pharmaceutical compounding unit. The second is production of Disinfection Agents for various fields and the third is production of Devi-ceuticals.

The company is GMP & GPP compliant and is certified ISO 9001:2015 and ISO 13485:2016.

There is always a constant need for **medicinal preparations** of non-registered drugs due to various reasons. Some of these reasons may be due to being a very limited usage and therefore no proprietary preparation available, a need for different properties such as Preservative Free eye drops or a proprietary drug shortage from normal suppliers. Usually these preparations are made in small batches, the company manufacturing in accordance with specific requests from medical institutions.

In our Disinfectant section, Concept is constantly striving to be a leader in disinfection technology, introducing and implementing new and innovative formulations to fulfill different needs in several different fields. Currently, the company manufactures several products for Human hygiene, Animal health, the Food industry and for Agriculture.

One of the most recent and advanced technologies is the introduction of a new chloroxidizer entity that incorporates a blue color. This is the first colored chloroxidizing agent in the world. The reason for developing the color in the compound is mainly as a safety measure but it also acts as an indicator. This new technological breakthrough places Concept's products in the first line of products intended for Infection Control. This compound is also known to be effective against the nCOVID-19 as stated by the WHO.

Devi-Ceuticals are registered medical devices in a pharmaceutical form such as: injectables, implants, ophthalmic drops, powders, sterile solutions tablets or other. Devices effect a physical action in the body without involving a Bio-Pharmacological response.

We are searching for companies who have established marketing and sales channels in the fields of Healthcare Establishments, Veterinary and Livestock Animal Husbandry, Agriculture and the Food Industry.

If you find interest please contact:

Yishai Freedman Dep. General Manager Tel. +972 -54-4250575 e-mail: <u>yishai@concept-Rx.co.il</u> Web Site: <u>www.concept-rx.co.il</u>





Bringing Creativity to World Markets

Dexcel Pharma is synonymous with innovation.

We excel at identifying opportunities and patient needs and then developing and commercializing real value-added products

Where others see obstacles, we see opportunities

Dexcel Pharma is Israel's largest private pharmaceutical company.

Founded in 1968, we develop, manufacture and market value-added branded and generic pharmaceuticals. With a diverse product portfolio that spans more than 85 branded and generic products in over 175 dosage forms, our products are sold in the US, the UK and Germany, via subsidiaries and through a trusted network of partners in more than 30 countries worldwide

Driven by Innovation

Dexcel Pharma[®] strives to meet the unmet needs of patients by applying innovative R&D in all areas of the Pharma value chain and exploiting unique capabilities with complex formulations and sophisticated regulatory strategies

Quality From Start to Finish

All Dexcel Pharma[®] sites deploy state-of-the-art equipment and are highly automated to ensure uncompromising quality

Global Reach

Dexcel Pharma[®] is a truly global enterprise, with over 80% of sales generated abroad. We are committed to long-term growth, entering new markets and constantly enhancing our product line

Proactive and Agile

Ability to identify opportunities and execute complex development and manufacturing in such a fast-paced competitive market has allowed us to create new gold standards in several niche areas, increase access to better and affordable dose formulations for patients and enjoy consistent success and growth

Solid Record of Accomplishment in Developing Novel Drug Formulations

300+ Marketing Authorizations	>10% of sales invested annually in R&D	50+ Patent & patent applications
#1 in the US OTC Market for Heartburn	10+ 505(b)(2) products in development	3 Manufacturing plants
1000+ Employees	15+ Gx products in development	5B+ Tablets produced per year

Strong, Long-lasting Partnerships

We continue to build our growing international network of quality partners, and look forward to uniting with new partners for future success

- New product development
- Product in / out-licensing
- New commercial agreements
- R&D technologies
- Novel drug delivery
- Manufacturing

Strategic Affiliates & Investments

Dexcel Pharma makes selective strategic investments in biopharma companies with complementary strategies and unique approach to innovation in our industry







BE PART OF OUR SUCCESS. REACH OUT TO US TO WORK TOGETHER

1 Dexcel St., Or Akiva, 3060000, Israel **(T. +**972 (0) 4 636 4000 **(E. <u>BD@dexcel.com</u> (W. <u>www.dexcel.com</u>**

Mapi Pharma Company Overview



- Mapi is a clinical stage pharmaceutical company, engaged in the development of high barrier-to-entry and high added-value life cycle management ("LCM") products that target large markets and generic drugs that include complex active pharmaceutical ingredients ("APIs") and formulations. The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company's pipeline, for the treatment of MS. The product is a LCM version of Copaxone[®], which requires injections daily or every other day. Mapi Pharma partnered with Mylan N.V. (NASDAQ: MYL) for GA Depot in an agreement under which Mylan was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs. Mapi is headquartered in Israel, with R&D facilities in Israel and China, an API production facility in the Neot-Hovav Eco Industrial Park and an aseptic manufacturing and a Fill & Finish facility for injectable Finished Dosage Forms in Jerusalem. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations.
- Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine. Ehud served as Teva Pharmaceuticals (VP at Teva API; Head of Copaxone global ops) and Makhteshim (Makhteshim Agan/ADAMA) (CEO)
- Lead product: GA Depot for the treatment of RRMS in Phase-3 & PPMS in Phase-3
- Mapi has R&D facilities in Israel and China, and GMP approved API & FDF sterile injections manufacturing sites in Israel

Lead Products Portfolio

505 (b) (2) Pathway Compound (Brand)	Indication	R&D/IP	Human PK	Phase II	Phase III and Registration
GA Depot (Copaxone®)	RRMS		Global Licensing		2023 🛄 Mylan
GA Depot (Copaxone®)	PPMS		Promising open study results		Phase III 2022
Pregabalin ER (Lyrica®)	Neuropathic Pain		Nhwa Regional Agreement		2021
Buspirone ER (BuSpar [®])	Anti-psychotic (anxiety)		Nhwa Regional Agreement		
ANDA Pathway Compound (Brand)	Indication		Human PK	Registration	Marketing
Fingolimod (Gilenya®)	RRMS		IL\EU\LA Marketing Agreen	nents Approved IL May 2017	Sales & Marketing IL/LA/EU 2019-2020
gCopaxone (Copaxone®)	RRMS		DMF 2021 ANDA 2022		
Paliperidone (Month/3 Months)	Schizophrenia		Regional Agreement Phase II		
Apremilast (Otezla)	Psoriasis				Sales & Marketing IL 2020
Aripiprazole (Ability Maintena®)	Schizophrenia				
GLP-1	Diabetes				
Loaded Exosomes for neurological indications	PD and MS				



Focused On

- Development of long-acting depot drugs: such as Glatiramer Acetate for RRMS and PPMS, Paliperidone and Aripiprazole or Schizophrenia, GLP-1 for Diabetes.
- Sterile injectable drugs: such as GA Depot, gCopaxone
- Development of long-acting oral solid forms: such as Pregabalin ER
- GMP Manufacturing of API
- GMP Manufacturing of Finished Dosage Forms (FDF): such as Fingolimod
- Loaded Exosomes for treating: such as Parkinson's disease, Alzheimer's, MS, ALS, GBM
- Combination treatments of stem-cells and cell derivatives such as exosomes with pharmaceuticals

Areas of Interest

- Investment: Mapi Pharma raised to-date: \$135 million (including \$20 million up-front) and is looking for additional capital to advance clinical programs such as Pregabalin ER for the EU market and other long-acting depot injectable programs and exosomes based treatments
- Collaboration: Mapi is open for collaboration in its fields of its expertise with pharmaceutical companies
- **GMP Manufacturing:** Mapi is open for specialty API, FDF and sterile injectable
- COVID-19: Approved vaccination F&F manufacturing

Key Individuals

Name	Select Experience
Ehud Marom, CEO and Chairman	Teva (VP at Teva API; Head of Copaxone global ops)Makhteshim (Makhteshim Agan/ADAMA) (CEO)
Uri Danon, Executive VP	BioCancell Therapeutics (President, CEO)Teva (Projects manager)
Dr. Shai Rubnov, VP R&D	NasVax (Manager of QA and regulatory affairs)
Alex Mogle, VP Corp. Dev.	 Makhteshim Agan (Secretary, IR, supply chain head)
Nir Bernstein, VP Finance	PwC (Senior Manager)

Additional Information and Contact Detals

For more information, please visit: <u>www.mapi-pharma.com</u> **Contact Person:** Alex Mogle, Vice President, Corporate Development, Mapi Pharma +972 52 6080297, <u>alex@mapi-pharma.com</u>



Unipharm was founded in 1975 in Israel and since its early days has been a dominant player in the Israeli Pharmaceutical Market.

Unipharm creates value in the full pharmaceutical value chain from research and development to manufacturing and successfully marketing generic pharmaceuticals, and takes pride in doing so in an innovative, responsible, and cost-efficient way.

Unipharm's corporate entrepreneurial culture and in-house development and GMP certified manufacturing capabilities capabilities are an integral part of Unipharm's effort to deliver quality products at affordable prices. Unipharm's new manufacturing facility was opened in 2017 and offers the latest technology in oral solids and oral solutions development and production. The Israeli GMP certification is recognized in the EU based on the Mutual Recognition Agreement between Israel and the EU.

Unipharm is well known in Israel for its involvement in intellectual property activities. In the current pharmaceutical-IP environment, Unipharm has the capabilities to accurately evaluate a product's patent protection suit and to act accordingly, including circumventing patents or invalidating them, enabling Unipharm to launch a generic version as soon as legally possible.

Unipharm's generic products are offered for license and supply agreements to all international pharma companies. Unipharm offers a product portfolio consisting of a broad range of high-quality generics for all major therapeutic areas. Unipharm is continuously expanding the product portfolio of both offpatent blockbusters and niche generic products within narrow disease areas.

Unipharm offers EU CTD dossiers to be registered internationally by its customers, who will receive the full regulatory support to achieve successful, swift registrations, and launch as early as possible in the respective markets.

For Unipharm's list of products, please email: BD@Unipharm.co.il

Contact person: Ms. Limor Dori Alon, Business Development Manager, Unipharm Ltd.

Office: +972-77-6135120 | Mobile: +972-54-2212241

CANNBIT – TIKUN-OLAM WORLDWIDE OPPORTUNITY

MEDICAL CANNABIS

TIKUN⊛OLA

Since 2006, with our strength in clinical research and depth knowledge and understanding from guidance thousands of patients, we have continually pushed industry standards forward, through strain genetics research, new product development, AgTech Innovation, state-of-the-art facility generating strong and established brands that create a significant influence on patient's health and quality of life.





Over 13 years of research



World renowed scientific board researches



>15,00 patient database



>30,000 patient treated in Israel, and tens of thousands globally



17 top tier publications and 19 on going researches



Award-winning strains



Over 35 clinical and preclinical researches



AgriTech and paitent oriented Innovation

Be part of our Global network!

Our aim is to collaborate with leading local Pharma entities and leverage our accumulated knowledge to create strong lucrative partnerships.

As our strategic partner, you will be exposed to our state-of-the-art capabilities, science and innovation across the value chain. Our Two-Stage Business Offer, as define hereinafter, harness our knowledge and ensure the establishment of an independent, vertically integrated venture in the destination country, that will join our global network of medical cannabis companies with more than a decade of experience via Tikun-Olam.



Tikun USA offering six proprietary strains, from its locations in California, Delaware and Florida.



Tikun Europe established to serve the growing needs of the European market. From its 56,000 m2 site in Corinth, it cultivates, processes and merchandises industrial and pharmaceutical cannabis.



Tikun Oceana Medifarm - Australia's first licensed medial cannabis producer.



FETTE PHARMA GRUPPE

Fette Pharma A pan-European company developing and marketing products in the pharmaceutical and cosmetisc industry for more than 40 years.

Stage One.

License-in of Cannbit final products in destination country. Advace upon achievement of agreed sales millestone.

Stage Two.

Tech-transfer process to harness Cannbit capabilities and experience for the establishment of local operation.

For more details contact:

Guy Haim - VP of business Development +972-54-5892528 | guyh@tikun-olam.org.il

+972-4-6575522 www.Tikun-Olam.org.il



Common Sense Ltd.- was established in 1999 by a group of scientists who wanted to invent and develop innovative solutions in the field of women's healthcare to improve women's lives throughout the world. Common Sense is a private company. Our team includes leading scientists in the fields of Chemistry and Biology, as well as Regulatory Affairs and Quality Control expert. Our R&D centre in Israel is at the sharp edge of invention and focuses on designing and developing unique and reliable diagnostic products. Our products are protected by several patents.

Our two main diagnostic products are the AL-Sense and the VS-Sense:

AL-SENSE—a diagnostic panty liner for detecting amniotic fluid leakage. This product is designated for professional use as well as for home use.

AL-SENSE utilizing advanced chemistry technology, results are available within moments, displaying with a simple color change (to blue) if the pregnant woman needs to be monitored and treated due to amniotic fluid leakage, or continue life as usual (no color change).

VS-SENSE—a diagnostic swab for detection of Bacterial Vaginosis (BV) and Trichomoniasis (TV). This product is designated for professional use (VS-SENSE Pro) as well as for home use (VS-SENSE OTC). VS-SENSE product assist in the diagnosis of potential vaginal infections. Vaginal symptoms such as itching, burning, or an unpleasant odor are hard to diagnose as they may be caused by either a bacterial infection, a parasitic infection (Trichomoniasis), or by a fungal infection (Candida), and sometimes two of these infection scan occur simultaneously.

The VS-SENSE swab changes color to blue within 10 seconds when in contact with vaginal secretion with elevated vaginal pH, in presence of Bacterial infection or Trichomonas Vaginalis, and will stay yellow in cases of Candida or where there is no infection.

Both products are very accurate and have CE and FDA clearance (AL-SENSE new generation FDA approval is pending).

Our products are being distributed all over the world for both the professional market (in 25/50 units packs) or pharmacies (in 2-20 units packs).

Areas of interest for collaboration:

- New product development
- Performing clinical trials in medical centers in Israel and out of Israel
- Consultation with global opinion leaders on clinical issues
- Production line development and improvement.
- Transition from development to production

Contact persons:

Adi Faintuch, Plant Manager, Common Sense- <adi@cs-commonsense.com> Ido Gal, R&D Manager, Common Sense- <ido@cs-commonsense.com> Dr. Hadar Kessary Shoham, Biological and Clinical Director- <hadar@cs-commonsense.com> Amir Krap- COO, Common Sense - <amir@cs-commonsense.com>



Medispec Ltd. 40 Hataasiya St., P.O. Box 292 Yehud, 5610103 Israel T. 03-6322088 | F. 03-6322099

Medispec is Looking for New Opportunities

- Medispec is looking for a strong <u>Distributor</u> in EAU, that can act both as local and regional Distributor under the brand name of Medispec. Proven record in capital medical equipment required, preferably in the Urology market.
- In addition, Medispec has innovative projects in the medical device field and is looking for <u>Investment and Funding</u>


For more information please contact us at: juliad@medispec-int.com

About Medispec

- Established in 1992, Privately owned
- Distributors in 85 countries
- Headquarters in USA, Maryland

Technology – Non Invasive Shock Wave Therapy

- Lithotripsy Non-invasive shock wave therapy for stone fragmentation (high energy shock waves)
- Angiogenesis regenerative medicine, creating newly formed blood vessels (low energy shock waves)





Savyon Diagnostics, a member of the Gamida B.V. group of companies, develops, manufactures and markets high quality diagnostic kits, reagents and systems for the detection of infectious diseases and genetic screening for more than 35 years through a worldwide network of over 80 distributors. Our tests and reagents are based upon various immunological and molecular biology techniques (Micro Arrays, RT-PCR, DNA/RNA purification, ELISA, MIF, IPA, Lateral Flow, functional enzymatic assays, *etc...*) and also maintains multiple patents related to these products.

Our company possesses the unique "know how" of producing quality core biologicals including antigens, antibodies, nucleic acid-based probes and bioconjugates, while using cutting-edge technologies and facilities (e.g., environmentally controlled spaces, BSL-3 laboratory, automated production lines, *etc...*) to manufacture the products to the high standards that laboratories and research institutions have come to depend upon.

Savyon Diagnostics is accredited with the highest international quality standards of research, development and manufacture, including ISO-13485. The company's products are all CE-IVD certified and those products sold in the USA, China, Brazil and Australia are FDA 510(k), CFDA, ANVISA and TGA approved, respectively. All our facilities are located in Ashdod and include >3,500 sqm of laboratories, production floors, warehouse and offices. Personnel includes 70 full-time employees.

Savyon Diagnostics has also established an Analytical Services unit. The unit complies with GMP guidelines as required by the International Conference on Harmonization (ICH) for active pharmaceutical ingredients as well as ISO-17025. The unit specializes in two main fields; Glycoanalysis and analytical services for the Cannabis industry.

Glycoanalysis services include: ● N-link glycan analysis by HPLC ● O-link glycan analysis by HPLC ● Profiling and quantitative analysis of sialic acid (NeuAc and NeuGc) ● Quantitative monosaccharaides analysis

Cannabis-related analytical services include:

Cannabinoids Profiling & Analysis
Terpens profiling
Custom Assay Design and Validation

The Analytical Unit complements the wide range of services offered by Savyon to the pharma, biotech, IVD and life sciences community. Other services include **Assay Development**, **Contract Manufacturing** and **logistics**, as well as **QA and RA consulting**.

Primary contacts:

Dr. Zvi Greenberg, VP R&D	zvi@savyondx.com 052-5351818	
Dr. Shimon Gross, VP Sales & Marketing	<u>shimon@savyondx.com</u>	052-3408550
Dr. Yehudit Amor, Head of Analytical Unit	<u>yehudit@savyondx.com</u>	052-3275716

Savyon Diagnostics Ltd. 3 Habosem St. 7761003 Ashdod, Israel



Simbionix simulators from 3D Systems are the result of decades of close collaborations with medical leaders located around the world. These training systems offer a realistic learning experience that helps develop confidence, provides experience and ultimately helps medical professionals achieve mastery of surgical procedures before they enter the operating room and engage with live patients. Simulators provide a safe environment in which learners can make mistakes as well as monitor their progress.

Patient safety via hands-on medical education is our goal.

Simulators support nearly every medical profession with task modules that range from tool proficiency to highly sophisticated step-by-step procedures. No other simulation company spans such a wide range of specialties. This achievement was only possible as the result of relationships with surgeons who confirmed the realistic look and feel of the platforms and procedures.

Not only have we sold thousands of simulators to hospitals, it is our partnerships with these institutions that has resulted in ongoing module and simulator creation. 3D Systems continually develops procedures for existing simulators as well as produces new training tools to support institutions' needs.

Utilizing the latest technology, simulators can be fully immersive with VR or AR, have haptics so that the feel resembles actual surgery, realistic graphics, endless case creation and even COVID-19 educational modules to name a few of the many capabilities.

Many systems are developed with leading medical societies who utilize our training systems for education and hands-on certification.

Additionally, we partner with medical device companies to provide unique customized simulation solutions used for device training enhancing both sales and marketing teams. This include portable systems for demonstrations and training which reduces training time and costs, helps surgeons use the medical device in a simulated environment to gain confidence and procedure knowledge before entering the operating room, show the medical device's ease-of-use, benefits and capabilities at medical tradeshows and events, replaces animal testing/usage and increase ROI as the use of a simulator reduces the time needed for skills acquisition and mastery, and is the ideal tool to support sales efforts and thus increase revenue and market share.

Possible collaboration: Hospital and teaching centers that build simulation centers and medical device companies that are looking for faster and safer ways to bring their device to the market

Please visit <u>www.simbionix.com</u> or email <u>healthcare@3dsystems.com</u>.

For further dialogue, please contact: Inbal Mazor | Vice President, Product Management & Marketing, Medical Simulation Email: <u>Inbal.Mazor@3DSystems.com</u>

3D Systems Simbionix | Golan Building, Corner of Golan and Hanegev St. |Airport City 70151 | Isarel

Company Profile:

Patho-Logica provides customized preclinical solutions for Biotech, Pharma, Medical-Device and Diagnostic companies and ventures. We have expertise in Efficacy and Safety analyses as well as a track-record of R & D and analytical successes in scientific PoM, PoP and PoC studies.

Headed by Senior Pathologist Dr. Emmanuel Loeb, our expert team will plan and perform pathological / histopathological services, consulting and management services to integrate with preclinical and clinical phases.

We will work with you to design efficient studies for key project issues as needed for the preclinical phase and to lay the groundwork for the rigors of clinical development:

- 1. **Pathological Services** Get reliable data analysis of histopathological end point for your product development.
- 2. Consulting Solutions Increase your product's value for the drug / device development process.
- 3. **Preclinical Management** Optimize your Product Development Plan.
- 4. Feasibility Studies Design and execute your PoC analysis based on our pathological methodology and tools.

Our clients range from Startups to Biotech to Pharma and include companies, CROs, hospitals and academia institutes.

Visit us:





+972-8-6190100 | e.loeb@patho-logica.com 3 Golda Meir St. | www.patho-logica.com Scientific Park, Ness Ziona | 7403648 Israel



Smart Assays Biotechnology

Smart Assays specializes in tailor-made R&D services for the Biotechnology industry. We would like to cooperate with start-ups and corporate VC early-stage investors, which are interested in early stage research and project validation.

Smart Assays provides research and development services to startups and pharmaceutical companies through a unique work model based on high-level researches providing customer-specific response according to its requirements, depending on the project.

The company focuses mainly on feasibility studies of due diligence projects and characterization of drug mechanism of action, development of tailor-made tests to meet FDA or EMA criteria and regulatory laws.

Our services reflect the company's unique work model – combination of chemistry and biology, which increases research capabilities.

Smart Assays provides services in three specialized research units. According to the customers' needs and the specific project, the company assigns the most appropriate researcher or staff for the project.

Biochemistry unit – the biochemical research focuses on: 1. perform experiments aimed at validation of seed and early stage projects. 2. Understanding the mechanism of action of drugs. **Histology unit**: The work scope of the histology unit includes solving the most challenging tasks in tissue structure research, with majority of tests being in favor of cancer research. **Bioanalytical unit** – This unit includes the following instruments:

- 1. LC-MS/MS HPLC equipped with Triple-quadrupole MS/MS, the gold standard for quantification of molecules in biological matrixes.
- 2. HPLC equipped with UV-VIS diode array, which enables 3D analysis of retention time vs. UV-VIS spectrum.
- **3.** Plate reader (spectrophotometer + spectrofluorometer) determination of full absorbance and 3D fluorescence spectrum of compounds.

Contact information:

Raphael Mayer, Ph.D. Founder & CEO <u>Mayer@assays.co.il</u> +972(0)54-7241251 <u>www.assays.co.il</u> Merav Marom Shamur Ph.D. Director of Operation and Project Manager <u>Merav@assays.co.il</u> +972(0)523942880



Biovac is a private owned company founded in 1989.

Biovac is engages in developing and producing of vaccines and pharmaceuticals for prevention and treatment of animal diseases.

Biovac company is a leading manufacturer of animal vaccines and pharmaceuticals in Israel and has its own distribution chain in order to distribute all the group's products.

The group owns plants for production of vitamin preparations, disinfectants and pest control products.

Biovac is a leading supplier to the local Israeli animal health market and provide comprehensive solutions for the animal husbandry branch.

Biovac group invests heavily in research and development. The group owns unique production laboratories such as a BSL3 laboratory and a Beta Lactam production alignment.

The production units of the group are under quality supervision of check laboratories, authorized and supervised by the Israeli Ministry of Health and Ministry of Agriculture.

The group's plants are ISO 9001 and Good Manufacturing Practice (GMP) approved.

For more details about our products and solution, please visit our site <u>www.biovac.co.il</u> ,or contact us to <u>vireo@biovac.co.il</u>

Looking for:

Business cooperation's in animal health and poultry vaccines.

Contact person:

Shay Yaron - Export Manager - shay@biovac.co.il

Rina Brosh – Export Department - vireo@biovac.co.il